By A study published in a journal by the University of New Mexico (UNM) Pharmacology frontier They found that patients who got high after using cannabis often experienced greater symptom relief.
entitled “Understanding the “high” mood and its role in medical cannabis patient outcomes‘, the researchers collaborated. ReLeaf App to study about 2,000 medical cannabis patients. Of these, he recorded more than 16,000 “dosing sessions” with participants using cannabis flowers.
Senior author and associate professor of psychology Jacob Vigil explained the goals behind this particular study. “Mood ‘high’ is poorly defined in the scientific literature, but is generally associated with both dysfunction and euphoria,” says Vigil. “While feeling ‘high’ is usually thought of as the purpose of recreational use, that limits the therapeutic potential of cannabis. This paper examines the validity of this hypothesis. However, they found that feeling “high” may be an unavoidable factor in using cannabis for medical purposes.
In the study, 49% of the researchers reported feeling high, which correlated with positive effects such as feeling “chills” and “happy,” while negative side effects included dry mouth and dry mouth. It turned out that he had bloodshot eyes. It was also found that 20% of participants reported negative side effects, while 7.7% experienced greater symptom relief and reported increased feelings of relaxation and peace.
The researchers sought to further define how high mood applies to both dysfunction and euphoria. “High mood was statistically significantly associated with feeling awkward, confused, dizzy, foggy, and paranoid, [as] In addition, you can get the effects of being happy, grateful, wonderful, and optimistic. “
It was also confirmed that there were many cases in which the mood was elevated and the symptoms were alleviated. “This suggests that feeling high may be a fundamental component of the effective use of cannabis as a medicine, rather than a tangential adverse effect that should be avoided in clinical practice.” UNM Newsroom.
Participants’ THC levels were strongly associated with feelings of elation, especially while using the vaporizer, compared to the effects experienced after smoking the flowers. Ultimately, the researchers noted, the results suggest that “increasing THC increases symptom relief only if the patient feels high.”
However, these observations hold true for both male and female participants, especially those suffering from anxiety, depression, pain, and fatigue. However, feeling high did not significantly reduce symptoms in those suffering from insomnia. Additionally, patients over the age of 40 were less likely to experience symptom relief when they got high.
According to Sarah Stis, lead author of the study and an associate professor of economics, the study will help researchers when studying cannabis and how it interacts with the human body. indicates the challenges faced by “The phytochemical composition of cannabis products is highly variable, and patients vary widely beyond even the factors included in this study, such as type of symptoms, gender, age, and cannabis experience.” Stis said. “Furthermore, factors that promote symptom relief, such as highs and THC, are associated with increased negative side effects such as functional impairment. It suggests that we are in a highly customized treatment rather than the traditional pharmaceutical model of standardized dosing.”
Researchers say clinicians should better understand the link between feeling high and symptom relief, and lawmakers believe even recreational cannabis use can lead to “unintended health benefits.” I suggested that we should understand something.
They concluded that future researchers should: consider the consequences For further consideration of this study. “Future studies will explore the psychological and physical effects of ingestion of other non-cannabinoid phytochemicals, such as terpenes, commonly occurring in cannabis plants, as well as exposure to heat (e.g., by temperature-controlled steam) and It will benefit from measuring pressure “affecting bioavailability and pharmacodynamics.” research ended.
